Flavones, quinolinones, quinazolinones, and aurones, and uses in ck2-mediated diseases
AssigneeThe Salk Institute for Biological Studies
InventorsIoana Ilinca Nitulescu, Fred H. Gage, James K. Tucker
Life of this patent
Estimating the term…
Abstract
Flavone, quinolinone, quinazolinone, and aurone derivatives are disclosed. The compounds have a structure according to formula I or formula II, or a pharmaceutically acceptable salt, hydrate, stereoisomer, or tautomer thereof. The compounds may inhibit CK2 enzyme activity. Some compounds selectively reduce or inhibit the CK2A2 enzyme subunit over the CK2A1 enzyme subunit.
Claims24
A compound according to formula I or formula II, or a pharmaceutically acceptable salt, hydrate, stereoisomer, or tautomer thereof:
- where each bond represented by “” is a single or double bond as needed to satisfy valence requirements;
- Q1 is C—R1 or N;
- Q2 is C—R2 or N;
- Q3 is C—R3 or N;
- Q4 is C—R4 or N;
- Q5 is C—R5, N, or N—Rb;
- Q6 is O, N, or N—Rb;
- Z is O, S, or N—Rb;
- R1 is X or H;
- R2 is H or —ORa;
- R3 is X or H;
- R4 is H;
- R5 is H;
- R6 is
- R7A and R7B independently are N or CH;
- R8 is H or X;
- R9 is hydroxy;
- R10A and R10B independently are X, —ORa, C1-C5 aliphatic, substituted C1-C5 aliphatic, or cycloaliphatic;
- R11 is O, —ORa, or N(Ra)2;
- R12 is
- furan-2-yl, or furan-3-yl;
- R13A and R13B independently are N or CH;
- R14 is H, X, or —ORa;
- R15 is —ORa, H, cyano, tetrazolyl, or —CO2Ra;
- R16 is H, X, —ORa, substituted aliphatic, cycloaliphatic, or alkynyl;
- each Ra independently is H or C1-C5 aliphatic;
- each Rb independently is H, C1-C5 aliphatic, or cycloaliphatic;
- and
- X is halo,
- wherein, when the compound has a structure according to formula I, at least one of Q1-Q4 is N, or Q5 is N or N—Rb, or Q6 is N or N—Rb, or R11 is other than O.
(canceled)
A compound, wherein the compound is:
19-22. (canceled)
24-28. (canceled)
31-36. (canceled)
Dependencies are inferred from the claim text.